Sugi Predict

Sugi Predict / Compounds / SCHEMBL486173

SCHEMBL486173

SCHEMBL486173

CC(=O)N(C)c1cc[c]cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ MAPT P10636 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ TP53 P04637 1/20 0.42
▸ HTT P42858 1/20 0.40
▸ NPC1 O15118 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ALOX15 P16050 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ FSCN1 Q16658 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ CASP6 P55212 1/20 0.36
▸ SRD5A1 P18405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7008098 0.83 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1RAB9AMAPTPOLB
SCHEMBL14341655 0.83 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1RAB9AMAPTPOLB
SCHEMBL6861323 0.82 KMT2A (0.36) SMN1; SMN2ALDH1A1RAB9AMAPTPOLB
SCHEMBL5404611 0.80 PLAU (0.33) SMN1; SMN2ALDH1A1RAB9AMAPTPOLB
SCHEMBL2483553 0.80 POLB (0.32) SMN1; SMN2ALDH1A1RAB9AMAPTPOLB
SCHEMBL3120599 0.79 GAA (0.40) POLBKMT2AHSD17B10
SCHEMBL27537843 0.78 ALDH1A1 (0.30) SMN1; SMN2ALDH1A1MAPT
SCHEMBL7641419 0.77 RAB9A (0.32) ALDH1A1RAB9AHSD17B10
SCHEMBL5516357 0.77 KMT2A (0.38) SMN1; SMN2ALDH1A1RAB9AMAPTNPC1
SCHEMBL2535672 0.77 PGR (0.41) SMN1; SMN2ALDH1A1RAB9AHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138395-B2 Interleukin-1β converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY (US) 2006-11-21 — — US claimed
US-7041696-B2 Interleukin-1β converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY (US) 2006-05-09 — — US claimed
US-7001899-B2 Interleukin converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY (US) 2006-02-21 — — US claimed
US-20050261283-A1 Methods and compositions for the treatment of graft failure BETH ISRAEL DEACONESS MEDICAL CENTER 2005-11-24 — — US claimed
EP-1509219-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GRAFT FAILURE Beth Israel Deaconess Medical Center (US) 2005-03-02 — — EP claimed
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY 2004-01-22 — — US claimed
US-20040009966-A1 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis THE PROCTER & GAMBLE COMPANY 2004-01-15 — — US claimed
US-20030236296-A1 Novel interleukin-1beta converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-25 — — US claimed
WO-2003094904-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GRAFT FAILURE BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2003-11-20 — — WO claimed
EP-0233461-B2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID CO (US) 2002-05-29 — — EP claimed
EP-0233461-B1 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID CO (US) 1996-03-20 — — EP claimed
EP-0588762-A1 Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs CIBA-GEIGY AG (CH) 1994-03-23 — — EP claimed
EP-0387201-B1 Mixture of dyestuffs and their use CIBA GEIGY AG (CH) 1994-02-02 — — EP claimed
EP-0529974-A1 Fungicidal 2-aryl-2-cyano-2-(aryloxyalkyl)ethyl-1,2,4-triazoles ROHM AND HAAS COMPANY (US) 1993-03-03 — — EP claimed
US-5131919-A Trichromic dyeing or printing CIBA-GEIGY CORPORATION (US) 1992-07-21 — — US claimed
EP-0387201-A1 Mixture of dyestuffs and their use CIBA-GEIGY AG (CH) 1990-09-12 — — EP claimed
US-4788195-A TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1988-11-29 — — US claimed
US-4716168-A STIMULANTS OF IMMUNE RESPONSE NORWICH EATON PHARMACEUTICALS, INC. (US) 1987-12-29 — — US claimed
EP-0233461-A2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1987-08-26 — — EP claimed
EP-0187705-A2 Imidazo(4,5-f)quinolines useful as immunomodulating agents Norwich Eaton Pharmaceuticals, Inc. (US) 1986-07-16 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261283-A1 Methods and compositions for the treatment of graft failure PDGFRB, PDGFRA, PDGFA SMN1; SMN2 2111/4885ALDH1A1 2323/4885RAB9A 4231/4885
US-20040009966-A1 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis TST, SYVN1, TXN2 SMN1; SMN2 3617/4885ALDH1A1 2280/4885RAB9A 3793/4885
US-20030236296-A1 Novel interleukin-1beta converting enzyme inhibitors IL1R1, IL1B, IL1RN SMN1; SMN2 4073/4885ALDH1A1 284/4885RAB9A 3771/4885
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors IL1B, IL1RN, IL1R1 SMN1; SMN2 4567/4885ALDH1A1 419/4885RAB9A 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.